摘要
食管癌是我国最常见的恶性肿瘤,恶性程度高、预后差,5 a生存率约15%~25%,其中90%为鳞癌。近几年,免疫治疗为多种肿瘤患者提供了新的治疗选择。围绕PD-1/PD-L1抑制剂在食管癌中作用机制及疗效的临床试验也在陆续开展,随着更多临床试验的结果公布,势必会将食管癌免疫治疗带入一个新的时代。
Esophageal cancer is a common malignant tumor in China with high degree of malignancy and poor prognosis. Its 5-year survival rate is about 15%~25%,and 90% of which is squamous cell carcinoma. In recent years, immunotherapy has provided new treatment options for patients with a variety of tumors. Clinical trials focusing on the mechanism and efficacy of PD-1/PD-L1 inhibitors in esophageal cancer were also being carried out. With the publication of more results of clinical trials,it is bound to bring immunotherapy for esophageal cancer into a new era.
作者
路遥
孟祥瑞
许孟丽
杨亚蓝
王峰
LU Yao;MENG Xiang-rui;XU Meng-li;YANG Ya-lan;WANG Feng(The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《食管疾病》
2020年第3期222-227,共6页
Journal of Esophageal Diseases
基金
国家自然科学基金面上项目(81672442)。
